m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02983)
Name
A-366
Synonyms
A 366; A366
    Click to Show/Hide
Status
Preclinical
Structure
Formula
C19H27N3O2
InChI
1S/C19H27N3O2/c1-23-16-12-14-15(21-18(20)19(14)6-4-7-19)13-17(16)24-11-5-10-22-8-2-3-9-22/h12-13H,2-11H2,1H3,(H2,20,21)
InChIKey
BKCDJTRMYWSXMC-UHFFFAOYSA-N
PubChem CID
76285486
TTD Drug ID
D0C5EG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Histone-lysine N-methyltransferase EHMT2 (EHMT2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Histone-lysine N-methyltransferase EHMT2 (EHMT2) is a therapeutic target for A-366. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of A-366 through regulating the expression of Histone-lysine N-methyltransferase EHMT2 (EHMT2). [1], [2]
References
Ref 1 N(6)-Methyladenosine Demethylase FTO Contributes to Neuropathic Pain by Stabilizing G9a Expression in Primary Sensory Neurons. Adv Sci (Weinh). 2020 May 27;7(13):1902402. doi: 10.1002/advs.201902402. eCollection 2020 Jul.
Ref 2 Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81. doi: 10.1016/j.molcel.2007.01.017.